Community Trust & Investment Co. Increases Position in IQVIA Holdings Inc. $IQV

Community Trust & Investment Co. raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 92,668 shares of the medical research company’s stock after purchasing an additional 4,388 shares during the period. Community Trust & Investment Co. owned about 0.06% of IQVIA worth $17,905,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the fourth quarter worth about $27,000. Gilpin Wealth Management LLC purchased a new stake in IQVIA during the 4th quarter valued at about $27,000. CrossGen Wealth LLC acquired a new stake in IQVIA in the 4th quarter valued at about $28,000. Activest Wealth Management lifted its stake in IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. Finally, Financial Freedom LLC purchased a new position in IQVIA in the 1st quarter worth approximately $25,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In related news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the sale, the insider owned 13,312 shares in the company, valued at $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 12,913 shares of company stock valued at $3,098,793. Insiders own 1.70% of the company’s stock.

IQVIA Trading Up 2.4%

NYSE IQV opened at $237.97 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The stock has a market capitalization of $39.17 billion, a P/E ratio of 29.53, a PEG ratio of 1.97 and a beta of 1.18. The firm’s 50-day moving average is $200.92 and its two-hundred day moving average is $186.95. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $251.36.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the previous year, the firm earned $2.81 EPS. The business’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has authorized a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on IQV shares. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Stifel Nicolaus raised their price objective on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Robert W. Baird increased their price target on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.